NASDAQ:KTTA Pasithea Therapeutics (KTTA) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free KTTA Stock Alerts $7.12 +0.14 (+2.01%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$7.00▼$7.2150-Day Range$5.80▼$8.3452-Week Range$5.25▼$17.40Volume1,144 shsAverage Volume12,884 shsMarket Capitalization$7.40 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Pasithea Therapeutics alerts: Email Address Pasithea Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside462.2% Upside$40.00 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPasithea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, Pasithea Therapeutics has a forecasted upside of 462.2% from its current price of $7.12.Amount of Analyst CoveragePasithea Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.06% of the float of Pasithea Therapeutics has been sold short.Short Interest Ratio / Days to CoverPasithea Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pasithea Therapeutics has recently increased by 4.55%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPasithea Therapeutics does not currently pay a dividend.Dividend GrowthPasithea Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KTTA. Previous Next 2.7 News and Social Media Coverage News SentimentPasithea Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders14.10% of the stock of Pasithea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.48% of the stock of Pasithea Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioPasithea Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Pasithea Therapeutics Stock (NASDAQ:KTTA)Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Read More KTTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KTTA Stock News HeadlinesFebruary 13, 2024 | finance.yahoo.comPasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004January 8, 2024 | finance.yahoo.comPasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:January 2, 2024 | msn.comPasithea Jumps as FDA Grants IND Status to Cancer TreatmentJanuary 2, 2024 | markets.businessinsider.comPasithea Therapeutics' IND Application For PAS-004 Gets FDA AcceptanceJanuary 2, 2024 | seekingalpha.comPasithea conducts 1-for-20 reverse stock split, gets FDA okay for studyJanuary 2, 2024 | finance.yahoo.comPasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsJanuary 1, 2024 | benzinga.comPasithea Therapeutics Stock (NASDAQ:KTTA) Dividends: History, Yield and DatesMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.December 28, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023December 19, 2023 | finance.yahoo.comPasithea Therapeutics Announces Results from 2023 Annual MeetingDecember 13, 2023 | msn.comWhy Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?December 11, 2023 | msn.comNeurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's WhyDecember 11, 2023 | markets.businessinsider.comPasithea Announces Positive In Vivo Preclinical Data For PAS-004December 11, 2023 | msn.comPasithea stock soars as high as 190% on preclinical dataDecember 11, 2023 | investorplace.comWhy Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?December 11, 2023 | finance.yahoo.comPasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNovember 29, 2023 | msn.comPasithea stock jumps 12% on update for anti-tumor drug PAS-004November 29, 2023 | markets.businessinsider.comPasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical DevelopmentNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNovember 9, 2023 | finance.yahoo.comPasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSSeptember 14, 2023 | finance.yahoo.comPasithea Therapeutics Corp. Announces Final Results of Tender OfferSeptember 7, 2023 | finance.yahoo.comPasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceAugust 1, 2023 | finance.yahoo.comPasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor functionJuly 20, 2023 | benzinga.comWhat's Happening With Pasithea Therapeutics Stock Today?July 20, 2023 | finance.yahoo.comPasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashSee More Headlines Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/18/2024Next Earnings (Estimated)3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KTTA CUSIPN/A CIK1841330 Webwww.pasithea.com Phone702-514-4174FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+462.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,940,000.00 Net MarginsN/A Pretax Margin-3,436.96% Return on Equity-45.98% Return on Assets-42.91% Debt Debt-to-Equity RatioN/A Current Ratio10.16 Quick Ratio10.16 Sales & Book Value Annual Sales$490,000.00 Price / Sales15.10 Cash FlowN/A Price / Cash FlowN/A Book Value$32.64 per share Price / Book0.22Miscellaneous Outstanding Shares1,040,000Free Float895,000Market Cap$7.40 million OptionableNot Optionable Beta0.90 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Lawrence Steinman BA (Age 76)M.D., Ph.D., Executive Chairman & Co-Founder Comp: $250kDr. Tiago Reis Marques M.D. (Age 47)Ph.D., CEO & Director Comp: $539.25kMr. Daniel H. Schneiderman (Age 46)Chief Financial Officer Comp: $327.91kDr. Yassine Bendiabdallah Ph.D. (Age 40)COO & Head of UK Clinics Dr. Graeme Currie Ph.D.Chief Development OfficerKey CompetitorsCadrenal TherapeuticsNASDAQ:CVKDSoligenixNASDAQ:SNGXCan-Fite BioPharmaNYSE:CANFVaccinexNASDAQ:VCNXObsEvaNASDAQ:OBSVView All CompetitorsInsidersLawrence SteinmanBought 1,500 shares on 6/2/2023Total: $12,900.00 ($8.60/share)View All Insider Transactions KTTA Stock Analysis - Frequently Asked Questions Should I buy or sell Pasithea Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pasithea Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KTTA shares. View KTTA analyst ratings or view top-rated stocks. What is Pasithea Therapeutics' stock price target for 2024? 1 brokerages have issued 12-month price targets for Pasithea Therapeutics' stock. Their KTTA share price targets range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 462.2% from the stock's current price. View analysts price targets for KTTA or view top-rated stocks among Wall Street analysts. How have KTTA shares performed in 2024? Pasithea Therapeutics' stock was trading at $7.40 at the start of the year. Since then, KTTA stock has decreased by 3.9% and is now trading at $7.1150. View the best growth stocks for 2024 here. When is Pasithea Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our KTTA earnings forecast. When did Pasithea Therapeutics' stock split? Pasithea Therapeutics's stock reverse split on Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Pasithea Therapeutics IPO? (KTTA) raised $17 million in an initial public offering on Wednesday, September 15th 2021. The company issued 2,898,551 shares at a price of $5.00-$7.00 per share. How do I buy shares of Pasithea Therapeutics? Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KTTA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThey said crypto was dead. It went up 100X.InvestorPlaceMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.